Поиск по репозиторию
Статья
Transplantation of ACE2- Mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia
2021
A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients without observed adverse effects. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11bmid regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-α was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2- and TMPRSS2- which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition. © 2020 Leng Z et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Цитирование
Похожие публикации
Версии
- 1. Version of Record от 2021-04-27
Метаданные
Название журнала
- Aging and Disease
Том
- 11
Выпуск
- 2
Страницы
- 216-228
Ключевые слова
- albumin; angiotensin converting enzyme 2; aspartate aminotransferase; bilirubin; brain derived neurotrophic factor; C reactive protein; chemokine receptor CXCR3; creatine kinase; creatine kinase isoenzyme; epidermal growth factor; fibrinogen; fibroblast growth factor; galanin; hemoglobin; interleukin 10; leukemia inhibitory factor; myoglobin; nerve growth factor; potassium; procalcitonin; scatter factor; sodium; transforming growth factor beta; troponin; tumor necrosis factor; adult; aged; Article; basophil count; breathing rate; CD4+ T lymphocyte; CD8+ T lymphocyte; clinical article; clinical outcome; clinical trial; computer assisted tomography; controlled study; coronavirus disease 2019; dyspnea; eosinophil count; erythrocyte count; female; fever; gene expression; glomerulus filtration rate; high throughput sequencing; human; human cell; immunomodulation; lung function; male; mass cytometry; mesenchymal stem cell transplantation; middle aged; monocyte count; natural killer T cell; neutrophil count; oxygen consumption; real time reverse transcription polymerase chain reaction; reverse transcription polymerase chain reaction; RNA sequencing; Severe acute respiratory syndrome coronavirus 2; virus pneumonia; weakness
Издатель
- International Society on Aging and Disease
Тип документа
- journal article
Тип лицензии Creative Commons
- CC
Правовой статус документа
- Свободная лицензия
Источник
- scopus
